BCM
NKTR icon

Bronte Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Bronte Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6M Buy
+202,500
New +$11.5M 1.44% 15

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bronte Capital Management's NKTR Position: Q1 2026 in Review

Bronte Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 198,256 shares worth $14.3M. The stake represents 1.41% of the portfolio and ranks #16 among its holdings.

215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Bronte Capital Management held 198,256 shares of Nektar Therapeutics worth $14.3M as of Q1 2026.
  • Nektar Therapeutics was a new Bronte Capital Management position in Q1 2026.
  • Nektar Therapeutics made up 1.41% of Bronte Capital Management's portfolio in Q1 2026, its #16 holding.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.